PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmiLibertas AcademicaJournal Home
 
Biomark Insights. 2010; 5: 33–38.
Published online 2010 May 4.
PMCID: PMC2879225

Elevated Serum Sorbitol and not Fructose in Type 2 Diabetic Patients

Abstract

Reductions in fasting serum fructose or erythrocyte sorbitol have been proposed as markers for early proof of mechanism in clinical development of aldose reductase (AR) inhibitors. However fructose is significantly impacted by meals and evaluation of erythrocyte sorbitol poses technical challenges. To more accurately assess the performance of these markers in biological samples, a gas chromatography-mass spectrometry assay was modified and validated. Serum was collected on three consecutive days from 13 healthy volunteers (HV) and 14 patients with type 2 diabetes mellitus (T2DM), and assayed for sorbitol and fructose using this assay. Serum fructose and sorbitol were relatively constant across the three days. Fasting fructose levels were comparable between the two groups (T2DM: 1.48 ± 0.49 mg/L; HV: 1.39 ± 0.38 mg/L, mean ± standard deviation, P = 0.61), but fasting sorbitol levels were significantly higher in diabetics (T2DM: 0.280 ± 0.163 mg/L; HV: 0.164 ± 0.044 mg/L, P = 0.02). Feeding resulted in a 5–6 fold increase in serum fructose levels, but only a 5%–10% increase in sorbitol. Only sorbitol remained significantly elevated pre- and post feeding in T2DM patients relative to HV. These data suggest that serum sorbitol may be a robust proof of mechanism biomarker and facilitate dose selection for clinical development of AR inhibitors.

Keywords: diabetic complications, polyol pathway, fructose, sorbitol

Introduction

According to the National Health and Nutrition Examination Survey (NHANES) 1999–2002, less than 50% of diabetic adults met or exceeded the American Diabetes Association (ADA) recommendation of HbA1c < 7%.1 These findings were despite the availability of insulin and several drug classes targeting glucose lowering. New classes of drugs targeting microvascular diabetic complications independent of glycemic control could therefore be of considerable value for the management and treatment of diabetes.

A number of metabolic pathways have been implicated as pathophysiologic contributors to microvascular diabetic complications, most notably, increased polyol pathway flux, protein kinase C activation, increased protein glycation leading to formation of advanced glycation end products (AGEs), and hexoamine pathway activation.2,3 All of these mechanisms, driven by hyperglycemia, are believed to contribute to oxidative-stress mediated tissue damage.

The predicted role for the polyol pathway in the etiology of diabetic complications is well documented.2,3 The two enzymes in the polyol pathway, aldose reductase (AR), which catalyzes the reduction of glucose to sorbitol, and sorbitol dehydrogenase (SDH), which catalyzes the oxidation of sorbitol to fructose, are abundant in tissues prone to diabetic complications. Under hyperglycemic conditions, increased flux of glucose through the polyol pathway is thought to increase oxidative stress in susceptible tissues, in part via elevating tissue NADH/NAD+levels.4,5

Selective inhibitors of AR and SDH have been shown to be of potential therapeutic utility in treating diabetic complications in pre-clinical animal models, with beneficial effects on motor nerve conduction velocities, proteinuria, and reduce markers of oxidative stress.69 AR inhibitors have also demonstrated therapeutic potential in clinical studies, improving markers for both neuropathy and nephropathy.1013 Some reports have suggested that diabetics have elevated blood fructose or erythrocyte sorbitol levels relative to healthy volunteers, presumably a consequence of elevated flux of glucose through the polyol pathway under hyperglycemic conditions. In fact, AR inhibitors have been demonstrated clinically to reduce erythrocyte sorbitol1417 and blood fructose levels.18,19 However technical and biological variables result in relatively high variability with these biomarkers.

The aim of this study was to investigate the absolute and relative differences in serum fructose and sorbitol measured across three days in healthy volunteers (HV) and patients with type 2 diabetes mellitus (T2DM), looking at sequential samples on each day from both fasting and fed states in subjects under well controlled conditions. A highly accurate and specific gas chromatography-mass spectrometry (GCMS) assay was validated to support this work, and the details of this assay are reported.

Patients and Methods

The study protocol was reviewed by ethical committees and informed consent was obtained from all subjects. Study subjects were confined to a clinical research unit for medical supervision and dietary control for the duration of the study (starting on day −1). HV subjects (n = 13) were free of any dietary supplements or medications for at least 7 days prior to the start of the study. T2DM patients (n = 14; screening HbA1c of 7.5%–10%) treated with 1–2 oral anti-diabetic agents were washed out of these medications for 7 days prior to the start of the study. Serum was collected on three sequential days at −30, −15, and 0 min before breakfast (fasting; after at least a 12 hour fast), and 60 and 120 min after a standardized breakfast (Boost High Protein® at 7 kcal/kg; 55% carbohydrate, 21% fat, 24% protein).

Sample preparation and GCMS analysis were based on the method of Küry and Keller.20 To 200 μL aliquots of standards (0.025–25 mg/L), QC samples (in human serum), and clinical study samples, 500 ng of fructose and sorbitol internal standards (D-[U13C6] fructose and D-[U13C6] sorbitol) were added. Samples were then deproteinized by ZnSO4—Ba(OH)2 extraction, dried under nitrogen, oximized (500 μL 1% o-methylhydroxylamine hydrochloride in pyridine; 2 hr at 70 °C), dried, derivatized (500 μL BSTFA [N,O-bis[Trimethylsilyl]trifluoroacetamide]; 20 min at 70 °C), and passed through 0.22 μm PVDF filters into autosampler vials. These samples were analyzed on an Agilent 5973 N Mass Specific Detector (MSD) interfaced with an Agilent 6890 A gas chromatograph equipped with a LEAP Technology GC PAL autosampler with a peltier-cooled sample rack (10 °C). Injection ports and GCMS interface were kept at 250° and 280 °C. Separations were performed on a Varian VF-5 ms fused silica column (30 M × 250 μm × 1 μm film thickness). Using helium as the carrier gas (0.8 ml/min), derivatized samples (5 μL) were injected at a 50:1 split ratio. The column temp was held at 220 °C for the duration of the 15-minute run. The MSD was run on EI-mode at 70 eV with SIM detection (m/z 307 for fructose, m/z 310 for fructose IS, m/z 319 for sorbitol and m/z 323 for sorbitol IS) for quantification. The MSD was turned off during the elution of glucose peaks.

Results

To accurately quantify sorbitol and fructose in biological samples, a highly sensitive GCMS assay was developed and validated. This assay had excellent intra (0.1%–1.3% CV) and inter-assay (2.9%–14.9%) precision (evaluated with neat, diluted, and spike serum samples) within the range of the standard curve (0.025–25 mg/L) in serum samples. A typical gas chromatography chromatogram for a human serum sample is shown in Figure 1. A peak of varying abundance eluting after the fructose peak was observed, but the identity of this peak was not determined. Based on spiking studies in human serum, we are sure this did not represent myo-inositol, glucose, fructose, or sorbitol. Finally, there was excellent agreement in pilot study samples between serum sorbitol levels and values measured in erythrocytes using this assay, however higher intra-assay variability was seen with analysis of erythrocyte samples.

Figure 1
Human serum gas chromatography chromatogram for quantification of fructose and sorbitol.

Using this assay, serum samples from T2DM and HV subjects were analyzed. The two subject populations were well matched for most demographic variables with no significant differences in gender, age, or BMI (Table 1). There were small but statistically significant differences in heart rate and blood pressure, and as expected highly significant differences in fasting blood glucose.

Table 1
Patient characteristics at baseline.a

Serum fructose and sorbitol levels (in mg/L) from 13 HV and 14 T2DM subjects were measured in blood samples collected on three sequential days from fasting (−30, −15, and 0 min before break-fast) and fed (60 and 120 min after breakfast) blood samples. Fasting and fed intra-subject variability was low (average 21% CV, range 5%–55%, highest for fed samples) so each subjects average levels were calculated. Fasting serum sorbitol levels were significantly higher in T2DM patients than HV subjects, but there was no significant difference in fasting fructose levels (Table 2). Feeding resulted in significant increases in serum fructose and sorbitol, but the magnitude of this increase was much greater for fructose (5.7–6.1 fold increases) than sorbitol (5%–10% increases; potentially as high as a 20% increase with elimination of all data from one T2DM patient that had considerably elevated sorbitol in fasting samples). Postprandial levels of sorbitol but not fructose remained significantly higher in T2DM patients compared to HV subjects. Finally, there was not a significant correlation between serum fructose or sorbitol levels and either heart rate or systolic blood pressure (data not shown). In addition, there did not appear to be a strong correlation between baseline glycemic control marker levels (HbA1c, C-peptide, or fasting glucose) and either sorbitol or fructose in the T2DM patients, however this should not be viewed as definitive due to the limited size of this study.

Table 2
Serum fructose and sorbitol concentrations under fasting and postprandial conditions.a

Discussion

This study shows that serum sorbitol levels, and not fructose, are elevated in fasting serum of T2DM patients with moderately controlled disease (HbA1c 8.41 ± 0.80%, mean ± standard deviation), and that serum sorbitol levels remain significantly elevated with feeding. This is in agreement with studies showing high erythrocyte sorbitol in diabetic patients,14,17,21,22 and animal models of diabetes.10,23 In fact, we saw similar magnitude of elevations in serum sorbitol in our T2DM patients (70% higher in fasting samples) as reported with erythrocyte sorbitol content by Asano et al (80% higher).15 Our data are in contrast to the work of Kawasaki et al18 who showed fasting serum fructose was increased in diabetic patients. However their study included diabetic patients with poorly controlled disease (HbA1c 10.7 ± 2.4%), for which 2 weeks hospitalization resulted in a reduction in fasting serum fructose to near normal levels, and reductions in other glycemic indicators. Therefore, the differences in glucose control may at least partially account for the differences in observed fasting serum fructose.

Several AR inhibitors have demonstrated their ability to reduce polyol pathway flux at the target tissue by decreasing sorbitol and/or fructose levels in sensory nerves of diabetic animal models or patients with diabetic neuropathy.9,12 The potent AR inhibitor fidarestat has also been shown to normalize erythrocyte sorbitol in diabetics.15 In our study, we observed elevations in serum sorbitol in subjects with T2DM compared to healthy volunteers, and using a mixed-meal tolerance test demonstrated that this elevation is relatively stable in the fed versus fasted state, as compared to the marked changes observed in serum fructose in the post-prandial state. This is consistent with similarly reported relative stability of erythrocyte sorbitol in the fed vs. fasted state.15 This suggests that sorbitol (serum or erythrocyte) is a more robust marker of polyol pathway flux than fructose, less likely to be influenced by acute changes in metabolic status.

The analytical method for measuring serum fructose and sorbitol levels described in detail in this report was used in a phase 1, multiple dose, clinical study to assess the pharmacodynamic effects of CP-642,931, a potent and selective inhibitor of SDH.24 In that study, inhibition of SDH in healthy subjects was associated with highly significant dose-dependent increase in serum sorbitol levels, reaching a maximum of a 152-fold increase at 7 days of dosing at 35 mg, the highest dose tested. However no significant changes in fasting serum fructose levels were observed.

The analytical method employed in these studies enables direct and accurate quantification of serum sorbitol and fructose. We have also validated this method for analyses of erythrocyte and urine samples. Furthermore, the method can be easily modified to enable quantification from tissue samples. This will enable further assessment of the relationships between tissue, serum and erythrocyte sorbitol and fructose, and importantly how these markers correlate with glycemic control and efficacy for potent polyol inhibitors developed to reduce or halt the progression of diabetic complications.

Acknowledgements

We thank TB Freeman, P Oates, M Novotny, C Xie, C Body, and S McNeill for their valuable assistance. Portions of this work were presented as a poster at the American Diabetes Association Meeting (San Diego, CA, June 10–14, 2005).

Abbreviations

AR
aldose reductase
SDH
sorbitol dehydroganase
T2DM
type 2 diabetes mellitus
HV
healthy volunteers
GCMS
gas chromatography-mass spectrometry

Footnotes

Disclosures

This manuscript has been read and approved by all authors. The authors are employees of Pfizer Inc who provided funding for this work. This paper is unique and is not under consideration by any other publication and has not been published elsewhere. The peer reviewers of this paper report no conflicts of interest. The authors confirm that they have permission to reproduce any copyrighted material.

References

1. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Healthy and Nutrition Examination Survey. Diabetes Care. 2006;29:531–7. [PubMed]
2. Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol. 2002;50:325–92. [PubMed]
3. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–25. [PubMed]
4. Barnett PA, Gonzalez RG, Chylack LT, Jr, Cheng HM. The effect of oxidation on sorbitol pathway kinetics. Diabetes. 1986;35:426–32. [PubMed]
5. Ido Y. Pyridine nucleotide redox abnormalities in diabetes. Antioxid Redox Signal. 2007;9:931–42. [PubMed]
6. Beyer-Mears A, Murray FT, Cruz E, Rountree J, Sciadini M. Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat. Pharmacology. 1992;45:285–91. [PubMed]
7. Tilton RG, Cheng K, Nyengaard JR, et al. Inhibition of sorbitol dehydrogenase: effects on vascular and neural dysfunction in streptozocin-induced diabetic rats. Diabetes. 1995;44:234–42. [PubMed]
8. Schmidt RE, Dorsey DA, Beaudet LN, et al. A potent sorbitol dehydrogenase inhibitor exacerbates sympathetic antonomic neuropathy in rats with streptozocin-induced diabetes. Exp Neurol. 2005;192:407–19. [PubMed]
9. Matasumoto T, Ono Y, Kurono M, Kuromiya A, Nakamura K, Bril V. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux. J Pharmacol Sci. 2009;109:203–10. [PubMed]
10. Green DA, Arezzo JC, Brown MB. the Zenarestat Study Group. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology. 1999;53:580–91. [PubMed]
11. Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic neuropathy: a 52-week multi-center placebo-controlled double-blind parallel group study. Diabetes Care. 2001;24:1776–82. [PubMed]
12. Brill V, Buchanan RA. the AS-3201 Study Group. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care. 2004;27:2369–375. [PubMed]
13. Oates PJ, Klioze SS, Schwartz PF, Boland AD. the Zopolrestat Diabetic Nephropathy Study Group. Aldose reductase inhibitor zopolrestat reduces elevated urinary albumin excretion rate in type 1 diabetes mellitus subjects with incipient diabetic nephropathy. J Am Soc Nephrol. 2008;19:642A.
14. Asano T, Saito Y, Kawakami M, Yamada N. Fidarestat Clinical Pharmacology Study Group. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. J Diabetes Complications. 2002;16:133–8. [PubMed]
15. Asano T, Saito Y, Kawakami M, Yamada N, Sekino H, Hasegawa S. Fidarestat Clinical Pharmacology Study Group. Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860) J Diabetes Complications. 2004;18:336–42. [PubMed]
16. Ando H, Takamura T, Nagai Y, Kaneko S. the Kanazawa University Multicenter Diabetes Study Group. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy. J Diabetes Complications. 2006;20:367–70. [PubMed]
17. Reddy GB, Satyanarayana A, Balakrishna N, et al. Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy. Mol Vision. 2008;14:593–601. [PMC free article] [PubMed]
18. Kawasaki T, Akanuma H, Yamanouchi T. Increased fructose concentrations in blood and urine in patients with diabetes. Diabetes Care. 2002;25:353–7. [PubMed]
19. Kawasaki T, Ogata N, Akanuma H, et al. Postprandial plasma fructose level is associated with retinopathy in patients with type 2 diabetes. Metabolism. 2004;53:583–8. [PubMed]
20. Küry D, Keller U. Trimethylsilyl-O-methyloxime derivatives for the measurement of [6,6−2H2]-D-glucose-enriched plasma samples by gas chromatography-mass spectrometry. J Chromatogr. 1991;572:302–6. [PubMed]
21. Malone JI, Knox G, Benford S, Tedesco TA. Red cell sorbitol, an indicator of diabetic control. Diabetes. 1980;29:861–4. [PubMed]
22. Kwang-Hyok S, Ui-Nam P, Sarkar C, Bhadra R. A sensitive assay of red cell sorbitol by high performance liquid chromatography: potential for diagnostic evaluation of diabetes. Clinica Chimica Acta. 2005;354:41–7. [PubMed]
23. Comazzi S, Bertazzolo W, Bonfanti U, Spagnolo V, Sartorelli P. Advanced glycation end products and sorbitol in blood from differently compensated diabetic dogs. Res Vet Sci. 2008;84:341–6. [PubMed]
24. Landau Z, Novotny MJ, Preston GM, et al. Pharmacokinetics, pharmacodynamics, tolerability, and safety of a novel sorbitol dehydrogenase inhibitor in healthy participants. J Clin Pharmacol. 2010;50:521–30. [PubMed]

Articles from Biomarker Insights are provided here courtesy of Libertas Academica